Article
Frontline treatment of AML in adults.
[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2017
Miyamoto Toshihiro, Kikushige Yoshikane, Yoshimoto And Goichi
Abstract excerpt
Despite recent progress in diagnosis and leukemogenesis based on genomic landscapes in acute myelogenous leukemia (AML), advances in AML treatment lag behind. Over the past four decades, combination chemotherapy with anthracycline and cytarabine remains the standard induction therapy. Subsequent post-remission consolidation therapy stratifies patients into favorable-risk, intermediate-risk, and unfavorable-risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
